Monitor for potential M&A activity given enhanced change-in-control severance terms. The timing following a proxy fight suggests management stability is a current board priority. Watch for any insider trading activity that might indicate confidence level in the company's direction.
Price Chart
Executive Summary
Corbus Pharmaceuticals renewed employment agreements with CEO Yuval Cohen and CFO Sean Moran, effective April 15, 2026. The agreements include base salaries of $673,625 for Cohen and $501,273 for Moran, with bonuses up to 60% and 40% of base salary respectively, and enhanced severance terms in case of change in control. This follows a recent contested proxy fight, suggesting board stability efforts.
Key Facts
- CEO Yuval Cohen's base salary set at $673,625 with bonus potential up to 60% of base salary
- CFO Sean Moran's base salary set at $501,273 with bonus potential up to 40% of base salary
- Agreements effective for two years through April 15, 2028
- Enhanced severance: 24 months base salary for Cohen and 18 months for Moran if terminated in connection with change in control
- Follows contested proxy fight with DEFA14A filing 14 days prior
Financial Impact
Potential annual cash compensation of up to $1.07 million for CEO and $701,000 for CFO including bonuses, plus significant change-in-control severance packages
Risk Factors
- Significant severance costs if change in control occurs
- Potential leadership stability concerns given need to reinforce executive retention after proxy fight
- Dilution risk from future equity awards not quantified in filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-159062 |
| Document: crbp-ex10_2.htm | 0001193125-26-159062 |
| Document: crbp-20260415.htm | 0001193125-26-159062 |
| Document: 0001193125-26-159062-index-headers.html | 0001193125-26-159062 |
| Document: 0001193125-26-159062-index.html | 0001193125-26-159062 |
| Document: 0001193125-26-159062.txt | 0001193125-26-159062 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $4.33 | awaiting T+60 | — | $3.99 (−7.85%) |
Sep 30, 2026 27d ago | SC 13G | $6.34 | awaiting T+60 | — | $3.99 (−37.07%) |
Sep 22, 2026 5w ago | Institutional Cluster | $7.88 | awaiting T+60 | — | $3.99 (−49.33%) |
Sep 14, 2026 6w ago | 8-K | $8.08 | awaiting T+60 | — | $3.99 (−50.62%) |
Sep 11, 2026 6w ago | Press Release | $8.08 | awaiting T+60 | — | $3.99 (−50.62%) |
Aug 12, 2026 10w ago | Insider Cluster | $10.08 | awaiting T+60 | — | $3.99 (−60.42%) |
Aug 10, 2026 11w ago | Insider Cluster | $9.51 | awaiting T+60 | — | $3.99 (−58.04%) |
May 26, 2026 22w ago | 8-K | $7.91 $9.99 | ▲ +26.30% | ▲ +23.57% | $3.99 (−49.56%) |
May 21, 2026 22w ago | 8-K | $11.51 $10.49 | ▼ −8.86% | ▼ −13.16% | $3.99 (−65.33%) |
May 14, 2026 23w ago | 8-K | $11.98 $9.46 | ▼ −21.04% | ▼ −24.62% | $3.99 (−66.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers